← Back to Search

Other

Multimodal Pain Management for Postoperative Pain

Phase 4
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Orthopaedic injury requiring surgery
Age 18 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial seeks to reduce opioid usage in orthopaedic surgery patients by testing a new pain management protocol.

Who is the study for?
Adults aged 18+ who need orthopaedic surgery at UCSD and can consent to participate are eligible. Excluded are those with multiple injuries, severe diseases not managed medically, pregnant women or those planning pregnancy within a year, prisoners, recent substance abusers, and anyone in another drug study recently.Check my eligibility
What is being tested?
The trial compares two pain management methods after orthopaedic surgery: a multimodal approach using Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine versus standard oral hydrocodone-acetaminophen. It's randomized and will assess opioid use, pain control, and function.See study design
What are the potential side effects?
Possible side effects include stomach issues from Ibuprofen/Acetaminophen; dizziness or fatigue from GABAPentin; local numbness from Bupivacaine; and constipation or drowsiness from hydrocodone-acetaminophen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I need surgery for a bone or joint injury.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Morphine equivalents used
Secondary outcome measures
Number of Complications
Pain Score (0-10, 0=no pain, 10=most severe pain)

Trial Design

2Treatment groups
Active Control
Group I: Standard oral hydrocodone-acetaminophen post-op managementActive Control1 Intervention
Group II: Multimodal pain post-op management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)Active Control1 Intervention

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,120 Previous Clinical Trials
1,521,307 Total Patients Enrolled
6 Trials studying Postoperative Pain
401 Patients Enrolled for Postoperative Pain

Media Library

Multimodal Pain Management (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05690282 — Phase 4
Postoperative Pain Research Study Groups: Standard oral hydrocodone-acetaminophen post-op management, Multimodal pain post-op management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)
Postoperative Pain Clinical Trial 2023: Multimodal Pain Management Highlights & Side Effects. Trial Name: NCT05690282 — Phase 4
Multimodal Pain Management (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05690282 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this trial currently open?

"According to clinicialtrials.gov, this clinical trial is actively enrolling participants. The first posting of the study was on May 17th 2021 and it has been recently edited as of January 9th 2023."

Answered by AI

How many individuals have enrolled in the experiment thus far?

"Affirmative. Clinicaltrials.gov confirms that this investigation, initially posted on May 17th 2021, is currently recruiting patients. The aim is to recruit a total of 100 individuals from 1 distinct site for the trial's duration."

Answered by AI

What potential risks should be considered with the implementation of a combined Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine medication regimen for post-operative pain management?

"There is ample evidence demonstrating the safety of this post-operative pain management system, so it was awarded a score of 3."

Answered by AI
~0 spots leftby May 2024